Two veterans of the ophthalmology field are reuniting to launch a portfolio-based biotech company EyeBio.
Former Roche research leader Tony Adamis is a co-founder of a new biotech aiming to bring innovation to the ophthalmology field currently dominated by a few big pharma players.
EyeBio has just completed a $65m series A funding from venture backers, who have also helped the biotech recruit a ‘team of disruptors’ to establish a
GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.
The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
